Explore 3 Stock Ideas & Industry Insights Download Free Report

small-cap

Forte Biosciences: Clinical Progress and Stronger Funding Offset by Cash Burn and Concentration Risk

Jul 27, 2026 | Team Kalkine
Forte Biosciences: Clinical Progress and Stronger Funding Offset by Cash Burn and Concentration Risk
Image source: Shutterstock

Forte Biosciences, Inc

Forte Biosciences, Inc (NASDAQ: FBRX) is a clinical-stage biopharmaceutical company developing FB102, an anti-CD122 monoclonal antibody targeting immune pathways linked to autoimmune diseases. The therapy is being evaluated for celiac disease and non-segmental vitiligo, with potential applications in alopecia areata, type 1 diabetes and other autoimmune conditions.

Recent Business Development


Disclaimer-

The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.

Past performance is not a reliable indicator of future performance.

Support

Hi! How can we help you today?

Loading…